155 related articles for article (PubMed ID: 28916658)
1. T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia.
Jing W; Gershan JA; Holzhauer S; Weber J; Palen K; McOlash L; Pulakanti K; Wesley E; Rao S; Johnson BD; Riese MJ
Cancer Res; 2017 Oct; 77(20):5676-5686. PubMed ID: 28916658
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
3. Diacylglycerol Kinase ζ Limits Cytokine-dependent Expansion of CD8
Andrada E; Liébana R; Merida I
EBioMedicine; 2017 May; 19():39-48. PubMed ID: 28438506
[TBL] [Abstract][Full Text] [Related]
4. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
5. Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes.
Arranz-Nicolás J; Martin-Salgado M; Rodríguez-Rodríguez C; Liébana R; Moreno-Ortiz MC; Leitner J; Steinberger P; Ávila-Flores A; Merida I
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33246984
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
Sehgal A; Whiteside TL; Boyiadzis M
Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
[TBL] [Abstract][Full Text] [Related]
7. Enhanced T cell responses due to diacylglycerol kinase zeta deficiency.
Zhong XP; Hainey EA; Olenchock BA; Jordan MS; Maltzman JS; Nichols KE; Shen H; Koretzky GA
Nat Immunol; 2003 Sep; 4(9):882-90. PubMed ID: 12883552
[TBL] [Abstract][Full Text] [Related]
8. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
[TBL] [Abstract][Full Text] [Related]
9. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
10. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
11. Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.
Blake SJ; Ching AL; Kenna TJ; Galea R; Large J; Yagita H; Steptoe RJ
PLoS One; 2015; 10(3):e0119483. PubMed ID: 25741704
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells.
Jung IY; Kim YY; Yu HS; Lee M; Kim S; Lee J
Cancer Res; 2018 Aug; 78(16):4692-4703. PubMed ID: 29967261
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
14. Diacylglycerol kinase zeta negatively regulates CXCR4-stimulated T lymphocyte firm arrest to ICAM-1 under shear flow.
Lee D; Kim J; Beste MT; Koretzky GA; Hammer DA
Integr Biol (Camb); 2012 Jun; 4(6):606-14. PubMed ID: 22546945
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
[TBL] [Abstract][Full Text] [Related]
16. Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance.
Wesley EM; Xin G; McAllister D; Malarkannan S; Newman DK; Dwinell MB; Cui W; Johnson BD; Riese MJ
Immunohorizons; 2018 Apr; 2(4):107-118. PubMed ID: 30027154
[TBL] [Abstract][Full Text] [Related]
17. Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Schlenker R; Olguín-Contreras LF; Leisegang M; Schnappinger J; Disovic A; Rühland S; Nelson PJ; Leonhardt H; Harz H; Wilde S; Schendel DJ; Uckert W; Willimsky G; Noessner E
Cancer Res; 2017 Jul; 77(13):3577-3590. PubMed ID: 28533272
[TBL] [Abstract][Full Text] [Related]
18. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy.
Lan J; Li R; Yin LM; Deng L; Gui J; Chen BQ; Zhou L; Meng MB; Huang QR; Mo XM; Wei YQ; Lu B; Dicker A; Xue JX; Lu Y
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):74-87. PubMed ID: 29619980
[TBL] [Abstract][Full Text] [Related]
19. Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis.
Zhou J; Peng H; Li K; Qu K; Wang B; Wu Y; Ye L; Dong Z; Wei H; Sun R; Tian Z
Immunity; 2019 Feb; 50(2):403-417.e4. PubMed ID: 30709740
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
